Please ensure Javascript is enabled for purposes of website accessibility

Biogen Is Building a COVID-19 Biobank With the Broad Institute

By Cory Renauer – Apr 17, 2020 at 6:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A consortium in Cambridge, Massachusetts, will test patients who have recovered from the coronavirus to advance the search for vaccines and treatments.

One of the world's largest biotechnology companies is making the best of a bad situation with a little help from its neighbors. In partnership with the Broad Institute of MIT and Harvard, Biogen (BIIB 0.85%) has formed a consortium that will build and share a COVID-19 biobank.

In early March, an executive from Biogen didn't realize they were COVID-19 positive while shaking hands with colleagues at the company's annual leadership meeting. Now, the cluster of cases that led to means there are a lot of Biogen employees in Massachusetts who were infected with the coronavirus and have had sufficient time to recover.

Laboratory technician with four test tubes.

Image source: Getty Images.

Volunteers from among those employees who have recovered from COVID-19, as well as close contacts of theirs who haven't been tested for the virus, will have their blood tested for the presence of antibodies against SARS-CoV-2. If the biobank can develop a large enough universe of data from those volunteers, researchers will have better odds of figuring out why some people who become infected recover without exhibiting serious symptoms, while others have much more severe cases.

Local cohort 

The Broad Institute will assemble blood samples from the infected individuals and their close contacts to build an anonymous set of medical and biological data. The COVID-19 biobank will become a free resource for researchers trying to develop vaccines and antiviral treatments. It will also be useful for epidemiologists who want to understand exactly how the disease spread through a relatively small group of the larger population. 

In addition to the Broad Institute of MIT and Harvard, Biogen will build and share the COVID-19 biobank with help from Partners HealthCare, Brigham and Women's Hospital, and Massachusetts General Hospital.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$197.41 (0.85%) $1.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.